Table 1.

Characteristics of participating studies of epithelial ovarian cancer

Study name (abbreviations)Study populationGenotyping platformStudy typeNumber of subjectsa
North America (US-CAN)
 Mayo Clinic Ovarian Cancer Study (MAY)Upper MidwestIllumina 610KClinic based359520
 North Carolina Ovarian Cancer Study (NCO)North CarolinaIllumina 610KPopulation based494654
 Tampa Bay Ovarian Cancer Study (TBO)TampaIllumina 610KPopulation based227169
 Familial Ovarian Tumor Study (TOR)Ontario, CanadaIllumina 610KPopulation based734524
 New England Case-Control Study of Ovarian Cancer (NEC)New EnglandIllumina 317K, 370KPopulation based133b142
US/CAN subtotal1,9472,009
United Kingdom (UK)
 SEARCH (SEA)EnglandIllumina 610KPopulation based1,118
 United Kingdom Ovarian Cancer Population Study (UKO)EnglandIllumina 610KPopulation based506
 Cancer Research UK Familial Ovarian Cancer Register (FOCR)EnglandIllumina 610KFamilial Cancer Register44
 Royal Marsden Hospital Study (RMH)EnglandIllumina 610KHospital based146
 UK 58 Birth Cohort (58 BC)England, Wales, ScotlandIllumina 550KCohort712
UK Subtotal1,814712
Poland (POL)
 Polish Ovarian Cancer Study (POL)Warsaw and Lodz, PolandIllumina 660wPopulation based212555
Overall total3,9733,276
  • aTotals represent the number of non-Hispanic white Europeans passing genotyping quality control criteria and meeting study site-specific inclusion/exclusion criteria.

  • bCases from NEC that were evaluated as part of this investigation represent postmenopausal advanced papillary serous carcinomas; 26 of these cases were ascertained as part of a hospital-based pre-operative study.